STEGLUJAN®

Hold Company

MSD SUB MERCK

Learn More

Dosage and Administration

TABLET;ORAL

Specification

5MG, EQ 100MG BASE; 15MG, EQ 100MG BASE

Indication

STEGLUJAN® is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Use

Instructions for Use

API

ERTUGLIFLOZIN
SITAGLIPTIN PHOSPHATE

API Structure

We Supply

ERTUGLIFLOZIN

Note:

null

SITAGLIPTIN PHOSPHATE

Note:

EP/USP
Facility GMP
Product GMP
ASMF/USMF/NMPA DMF

Drug Patent

Patent No	Expiration Date
7326708	2026/11/24
7326708*PED	2027/5/24
8080580	2030/7/13
9308204	2030/10/21
9439901	2030/10/21

API Patent

Patent No	Expiration Date
8080580	2030/7/13
9308204	2030/10/21
9439901	2030/10/21

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.